Intelligent Bio Solutions Inc. (INBS) NASDAQ
2.65
+0.08(+3.11%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.65
+0.08(+3.11%)
Currency In USD
Address
142 West 57th Street
New York City, NY 10019
United States of America (the)
Phone
646 828 8258
Website
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
50
First IPO Date
December 23, 2020
| Name | Title | Pay | Year Born |
| Harry Simeonidis | President & Chief Executive Officer | 425,726 | 1968 |
| Spiro Kevin Sakiris | Chief Financial Officer | 314,417 | 1962 |
| Anna Turkington | Vice President of Marketing | 0 | N/A |
| Callistus Sequeira | Vice President of Global Quality & Operations | 0 | N/A |
| Doug Heath | Vice President of Global Sales | 0 | N/A |
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.